Golar LNG Partners LP Announces Record Date and Meeting Date for Special Meeting for Proposed Merger With New Fortress Energy
Golar LNG Partners LP (NASDAQ: GMLP) (“GMLP”) announced today that it has established a record date of January 25, 2021 for a special meeting of its unitholders currently planned to take place on February 24, 2021. At the special meeting, the holders of GMLP’s common units will vote on the previously announced proposed merger of GMLP and an indirect subsidiary of New Fortress Energy Inc. (“NFE”), as contemplated by GMLP’s Third Amended and Restated Agreement of Limited Partnership dated October 31, 2017. GMLP common unitholders of record at the close of business on January 25, 2021 will be entitled to receive notice of the special meeting and to vote at the special meeting.
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements concerning future events. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the words “believe”, “anticipate”, “expect”, “estimate”, “project”, “will be”, “will continue”, “will likely result”, “plan”, “intend” or words or phrases of similar meanings. Such statements are generally not historical in nature and specifically include statements about GMLP’s plans, strategies, business prospects and changes and trends in the business in which it operates. Forward-looking statements in this press release include statements relating to NFE’s proposed acquisition of GMLP and other statements that are not historical facts. These statements involve known and unknown risks and are based upon a number of assumptions and estimates that are inherently subject to significant uncertainties and contingencies, many of which are beyond GMLP’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements. New factors emerge from time to time, and it is not possible for GMLP to predict all of these factors. Further, GMLP cannot assess the impact of each such factor on its business or the extent to which any factor, or combination of factors, may cause actual results to be materially different from those contained in any forward-looking statement.
Specific factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to: (i) changes in federal, state, local and foreign laws or regulations to which NFE or GMLP is subject; (ii) the risk that the proposed transaction may not be completed in a timely manner or at all; (iii) GMLP’s ability to receive, on a timely basis or otherwise, the required approval of the proposed transaction by its common unitholders; (iv) the possibility that competing offers or acquisition proposals for GMLP will be made; (v) the possibility that any or all of the various conditions to the consummation of the GMLP transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); and (vi) other risk factors identified herein or from time to time in GMLP’s periodic filings with the SEC. These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of GMLP’s forward-looking statements. Other known or unpredictable factors could also have material adverse effects on future results.
GMLP does not intend to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in GMLP’s expectations with respect thereto or any change in events, conditions or circumstances on which any such statement is based.
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION
In connection with the proposed merger, GMLP filed a Report on Form 6-K with the SEC on January 19, 2021, which contains, among other things, a copy of the merger agreement, and GMLP will furnish to its unitholders a proxy statement and other relevant documents. This press release is not a substitute for the merger agreement or proxy statement or for any other document that GMLP may file with the SEC in connection with the proposed transactions. BEFORE MAKING ANY VOTING DECISION, GMLP’S UNITHOLDERS ARE URGED TO READ THE MERGER AGREEMENT AND THE PROXY STATEMENT WHEN EACH BECOMES AVAILABLE AND ANY OTHER DOCUMENTS TO BE FILED WITH THE SEC IN CONNECTION WITH THE PROPOSED MERGER OR INCORPORATED BY REFERENCE IN THE PROXY STATEMENT BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER.
Investors and security holders will be able to obtain, free of charge, a copy of the proxy statement (when available) and other relevant documents filed with the SEC from the SEC’s website at http://www.sec.gov. In addition, the proxy statement, GMLP’s annual report on Form 20-F and its other filings with the SEC will be available free of charge through GMLP’s website: www.golarlngpartners.com, as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.
Golar LNG Partners LP
January 19, 2021
Questions should be directed to:
c/o Golar Management Ltd - +44 207 063 7900
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Synchronoss Announces Appointment of Jeff Miller as Permanent CEO and President8.3.2021 15:21:20 CET | Press release
BRIDGEWATER, N.J., March 08, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, today announced that its Board of Directors has confirmed Jeff Miller as its President and Chief Executive Officer. Miller had been serving as interim President and CEO of Synchronoss since September 2020 and joined Synchronoss in 2018 as Chief Commercial Officer. Prior to coming to Synchronoss, Miller was President of the Technology Group for IDEAL Industries, a firm focused on designing and delivering solutions for smart commercial buildings and spaces. He also served 16 years with Motorola, most recently as Corporate Vice President and General Manager of Operations in North America for Motorola Mobility, LLC, a division of Lenovo. Miller also held various leadership positions in sales management, marketing, and product management at AT&T during an 11-year tenure. “I have had the opportunity to work closely with
AMG Advanced Metallurgical Group N.V. Announces Long-Term Spent Catalyst Recycling Agreement8.3.2021 15:00:00 CET | Press release
Amsterdam, 8 March 2021 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") is pleased to announce that AMG Vanadium has signed a new long-term, multi-year agreement to process and recycle spent catalysts from a major oil refinery operator in North America. Located in Cambridge, Ohio, AMG Vanadium specializes in the environmentally beneficial conversion of oil refinery and power plant waste products into specialty metals used by global steel producers in automotive, energy transmission and infrastructure applications. By using materials that would otherwise be discarded as waste, AMG Vanadium facilitates environmental stewardship, energy conservation and resource recovery. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & ch
Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro8.3.2021 14:15:00 CET | Pressemelding
Företagsmeddelande, insiderinformation, Helsingfors den 8 mars 2021 kl. 15.15 (EET) Nexstim Abp offentliggör EU-tillväxtprospekt avseende en företrädesemission på 6,6 miljoner euro Nexstim Abp (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolag”) meddelar med hänvisning till bolagets företagsmeddelande utgiven tidigare i dag, om en företrädesemission av cirka 6,6 miljoner euro att bolaget har upprättat ett EU-tillväxtprospekt som Finansinspektionen godkände den 8 mars 2021. Bolagets styrelse beslutade att offentliggöra EU-tillväxt prospektet den 8 mars 2021 och det ska notifieras till Sverige. EU-tillväxtprospektet på finska läggs omkring den 8 mars 2021 ut på Nexstims webbplats på www.nexstim.com/investors/rights-issue-2021 och tillhandahålls också på bolagets registrerade adress på Elimäkigatan 9 B, 00510 Helsingfors. Dessutom görs EU-tillväxtprospektet på finska tillgängligt på receptionen på Nasdaq Helsinki på Fabiansgatan 14, 00100 Helsingfors. EU-tillväxtprospektet på engelska och en
Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue8.3.2021 14:15:00 CET | Press release
Company announcement, inside information, Helsinki, 8 March 2021 at 3.15 PM (EET) Nexstim Plc publishes an EU growth prospectus regarding EUR 6.6 million subscription rights issue Nexstim Plc (NXTMH:HEX, NXTMS:STO) (”Nexstim” or ”Company”) announces with reference to the company announcement published earlier today regarding a subscription rights issue totaling approximately EUR 6.6 million , that the Company has prepared an EU growth prospectus which the Finnish Financial Supervisory Authority (FIN-FSA) has approved on 8 March 2021. The Board of Directors of Nexstim has resolved to publish the EU growth prospectus on 8 March 2021 and it shall be notified to Sweden. Finnish version of the EU growth Prospectus will be available approximately on 8 March 2021 on the Nexstim’s website at http://www.nexstim.com/investors/rights-issue-2021 and at the registered office of the Company at Elimäenkatu 9 B, 00510 Helsinki. Moreover, the Finnish version of the EU growth prospectus will be availabl
Saniona får återkoppling från FDA gällande den regulatoriska vägen framåt för Tesomet mot hypotalamisk fetma8.3.2021 14:00:00 CET | Pressemelding
PRESSMEDDELANDE 8 mars 2021 Saniona (OMX: SANION), ett biofarmaceutiskt företag med klinisk utveckling fokuserad på sällsynta sjukdomar, meddelar idag att det amerikanska läkemedelsverket FDA lämnat återkoppling som ytterligare klarlägger det regulatoriska spåret för Tesomet som behandling av hypotalamisk fetma (HO). Baserat på den erhållna återkopplingen går Saniona vidare med planerna att inleda en fas 2b-studie på HO under första halvåret innevarande år. ”I dagsläget finns inga godkända mediciner för hypotalamisk fetma, en sällsynt sjukdom sekundär till skador i hypotalamus. Sjukdomen kännetecknas av svårhanterlig viktuppgång och kompliceras av okontrollerbar hunger”, säger Rudolf Baumgartner, Sanionas Chief Medical Officer och Head of Clinical Development. ”Återkopplingen från FDA är uppmuntrande, och vi ser fram emot att fortsätta den konstruktiva dialogen med myndigheten medan vi förbereder starten av vår kliniska fas 2b-studie med Tesomet.” Som Saniona tidigare meddelat har FDA
Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity8.3.2021 14:00:00 CET | Press release
PRESS RELEASE March 8, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it received feedback from the U.S. Food and Drug Administration (FDA) providing further clarity on a regulatory path for Tesomet in the treatment of hypothalamic obesity (HO). Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year. “There is currently no medicine approved for hypothalamic obesity, a rare disease secondary to hypothalamic injury, characterized by intractable weight gain and complicated by uncontrollable hunger,” said Rudolf Baumgartner, M.D., Chief Medical Officer and Head of Clinical Development at Saniona. “We are encouraged by this feedback from the FDA and look forward to continuing a constructive dialogue with them as we prepare to initiate our Phase 2b clinical trial with Tesomet.” Saniona previously announced that the FDA had highlighted the potential for off-lab
Signify share repurchase periodic update8.3.2021 13:00:00 CET | Press release
Press Release March 8, 2021 Signify share repurchase periodic update Eindhoven, the Netherlands –Signify (Euronext: LIGHT), the world leader in lighting, today announced that it has repurchased 160,815 shares in the period March 1 to March 5, 2021. The shares were repurchased at an average price of EUR 36,64 per share and an aggregate amount of EUR 5.9 million. These repurchases were made as part of the company’s repurchase program, which was announced on February 25, 2021. Signify will use the shares to cover obligations arising from its long-term incentive performance share plan and other employee share plans. The total number of shares repurchased under this program to date is 216,690 shares for a total consideration of EUR 7.9 million. Details on the share buyback transactions can be found here. --- END --- For further information, please contact: Signify Investor Relations Thelke Gerdes Tel: +31 6 1801 7131 E-mail: firstname.lastname@example.org Signify Corporate Communications Elco va